Onconic Therapeutics: "Expanding OCN-501 Development as a Cachexia Treatment"
Three OCN-501 Preclinical Studies to Be Presented at International Conference
Expanding Development as an Independent Treatment for Muscle Disorders
Onconic Therapeutics is expanding the development of its next-generation muscle metabolism drug OCN-501 beyond its use in combination with incretin-based obesity treatments, such as glucagon-like peptide-1 (GLP-1) drugs, to preserve muscle, targeting muscle-wasting diseases such as cachexia.
Onconic Therapeutics announced on November 19 that three preclinical studies of OCN-501 for cachexia had been selected for poster presentations at the 19th International Conference on Cachexia, Sarcopenia and Muscle Wasting, SCWD 2026, to be held in Washington, D.C., from December 10 to 12 (local time).
OCN-501 is an oral small-molecule drug under development to maintain energy metabolism homeostasis in muscle and alleviate signals that trigger protein breakdown. At ObesityWeek 2026, the company presented preclinical findings showing that, when used in combination with semaglutide, OCN-501 maintained weight-loss effects while significantly improving muscle mass-related indicators and significantly suppressing declines in grip strength, a measure of actual muscle function. Fat tissue also decreased further.
The company said that the selection of three additional cachexia studies for SCWD 2026 expands the potential for OCN-501 to be developed as an independent treatment for muscle metabolism disorders, beyond its use in combination with obesity treatments. Detailed methods and results of the cachexia studies will be presented at the conference.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An Onconic Therapeutics official said, "The core value of OCN-501 is that it is a new drug targeting both muscle mass and function, and that it can be developed for a range of muscle disorders, including in combination with obesity treatments. We aim to improve the quality of weight loss in the obesity treatment field and develop an independent treatment for cachexia."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.